Gilead Sciences 
 
1Q Revenues: $2.5 billion (+11%)
 
1Q Earnings: $722.2 million (+64%)
 
Comments: Antiviral product sales increased 7% to $2.1 billion driven by Complera/Eviplera ($148.2 million, +184%) and Stribild ($92.1 million), partially offset by an 8% decrease in Truvada sales to $702.0 million. Cardiovascular product sales increased 26% to $214.4 million, driven primarily by strong Letairis sales ($118.1 million, +35%).